Abstracts tagged "Raynaud’s phenomenon"

Abstract Number: 1880 • 2015 ACR/ARHP Annual Meeting
Circulating Microparticle Populations May Differentiate Between Connective Tissue Diseases.
Eoghan M. McCarthy^1,2, Daniel Moreno-Martinez³, Fiona Wilkinson⁴, Neil J McHugh^5,6, Ian N. Bruce^7,8, Yvonne Alexander³, John D. Pauling^6,9 and Ben Parker^7,8, ¹The University of Manchester, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, Mmanchester, United Kingdom, ²NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospital NHS Foundation Trust, Manchester, United Kingdom, ³Healthcare Science Research Institute, Manchester Metropolitan University, Manchester, United Kingdom, ⁴School of Healthcare Science, Manchester Metropolitan University, Manchester, United Kingdom, ⁵Rheumatology, Bath Institute of Rheumatic Diseases, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁶Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, ⁷Central Manchester University Hospital NHS Foundation Trust and Manchester Academic Health Science Centre, NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom, ⁸Stopford Building, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ⁹Upper Borough Walls, Royal National Hospital for Rheumatic Disease, Bath, United Kingdom
Background/Purpose: Microparticles (MPs) are membrane-bound vesicles derived from vascular and intravascular cells such as endothelial cells (EMPs) and platelets (PMPs). Circulating MPs levels are altered…
Abstract Number: 1894 • 2015 ACR/ARHP Annual Meeting
Calcium Channel Blockers Are More Effective in the Treatment of Primary Raynaud’s Phenomenon Compared to Secondary: A Meta-Analyis
Janet E. Pope¹, Fadumo Rirash², Paul Tingey³, Sarah Harding⁴, Lara J. Maxwell⁵, Peter Tugwell⁶, Jordi Pardo⁷, Elizabeth Ghogomu⁸ and George A. Wells⁹, ¹University of Western Ontario, London, ON, Canada, ²Medicine/Rheumatology, University of Western Ontario, London, ON, Canada, ³Faculty of Medicine, University of Queensland, Brisbane, Australia, ⁴ERLanger, ERLanger, KY, ⁵Centre for Global Health, Institute of Population Health, University of Ottawa, Ottawa, ON, Canada, ⁶Center For Global Health, Institute of Population Hlth, Ottawa, ON, Canada, ⁷University of Ottawa, Ottawa, ON, Canada, ⁸University of Ottawa, Cochrane Musculoskeletal Group, Ottawa, ON, Canada, ⁹Cardiovascular Research Reference Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada
Background/Purpose: To assess the benefits and harms of calcium channel blockers (CCBs) versus placebo for the treatment of Raynaud's phenomenon (RP) comparing primary to secondary…
Abstract Number: 1896 • 2015 ACR/ARHP Annual Meeting
Early Signs, Symptoms and Auto-Antibodies to Predict Diffuse Cutaneous or Limited Cutaneous Systemic Sclerosis at First Presentation
WMT van den Hombergh¹, HKA Knaapen-Hans¹, Patricia E. Carreira^2,3, FHJ van den Hoogen¹, Jaap Fransen¹ and MC Vonk¹, ¹Rheumatology, Radboud University Medical Centre, Nijmegen, Netherlands, ²Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ³Rheumatology Unit, Hospital 12 de Octubre, Hospital 12 de Octubre, Madrid, Spain
ABSTRACT Background/Purpose: Diffuse cutaneous systemic sclerosis (dcSSc) is associated with a poorer prognosis compared to limited cutaneous SSc (lcSSc), due to earlier and more severe…
Abstract Number: 1928 • 2015 ACR/ARHP Annual Meeting
Isolation and Initial Characterization of Dermal Vascular Smooth Muscle Cells in Systemic Sclerosis
Shadia Nada¹, Farouk Abu Alhana², Yongqing Wang², Nezam Altorok³ and Bashar Kahaleh⁴, ¹Internal Medicine, Divison of Rheumatology, The University of Toledo, Toledo, OH, ²The University of Toledo, Toledo, OH, ³Internal Medicine, Division of Rheumatology, The University of Toledo, Toledo, OH, ⁴Medicine/Rheumatology, The University of Toledo, Toledo, OH
Background/Purpose: Nearly all patients with Systemic sclerosis (SSc) suffer from vascular dysfunction as illustrated by the uniform presence of Raynaud’s phenomena. The role of vascular…
Abstract Number: 2256 • 2015 ACR/ARHP Annual Meeting
Clinical Characteristics, Laboratory Findings and Nailfold Capillaroscopy Microscopy Patterns in a Monocentric Series of 123 Patients with Idiopathic Pernio
Thi Phuong Uyen Doan¹, Sara Hussein¹, Martial Koenig² and France Joyal¹, ¹Université de Montréal, Montreal, QC, Canada, ²Internal Medicine, Hôpital Notre-Dame du CHUM, Montréal, QC, Canada
Background/Purpose: Few studies have looked at the characteristics of patients diagnosed with pernio and the significance of the use of capillaroscopy in these patients. The…
Abstract Number: 2379 • 2015 ACR/ARHP Annual Meeting
Clinical Follow-up Predictors of Disease Pattern Change in Anti Jo-1 Positive Antisynthetase Syndrome: Results from a Multicenter, International and Retrospective Study
Franco Franceschini¹, Elena Bartoloni-Bocci², Santos Castañeda³, Laura Nuno⁴, Carlo Alberto Scirè⁵, Francisco Javier López-Longo⁶, Julia Martínez-Barrio⁷, Ilaria Cavazzana¹, Paolo Airò⁸, Javier Bachiller Corral⁹, Alberto Sifuentes Giraldo¹⁰, Rossella Neri¹¹, Simone Barsotti¹², Roberto Caporali¹³, Carlomaurizio Montecucco¹⁴, Marcello Govoni¹⁵, Renato La Corte¹⁵, Federica Furini¹⁵, Florenzo Iannone¹⁶, Margherita Giannini¹⁷, Enrico Fusaro¹⁸, Simone Parisi¹⁹, Giuseppe Paolazzi²⁰, Giovanni Barausse²¹, Raffaele Pellerito²², Alessandra Russo²², Lesley Ann Saketkoo²³, Norberto Ortego-Centeno²⁴, Luca Quartuccio²⁵, Christof Specker²⁶, Andreas Schwarting²⁷, Kostantinos Triantafyllias²⁸, Carlo Selmi²⁹, Fausto Salaffi³⁰, Marco Amedeo Cimmino³¹, Annamaria Iuliano³², Fabrizio Conti³³, Gianluigi Baiocchi³⁴, Elena Bravi³⁵, Anna Ghirardello³⁶, Trinitario Pina³⁷, Miguel A. Gonzalez-Gay³⁸, Lorenzo Cavagna³⁹ and AENEAS (American and European NEtwork of Antisynthetase Syndrome) collaborative group, ¹Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ²Department of Medicine, Rheumatology Unit, University of Perugia, Perugia, Italy, ³Rheumatology, H.U. La Princesa, Madrid, Spain, ⁴Rheumatology, Hospital Universitario La Paz, Madrid, Spain, ⁵Epidemiology Unit – Italian Society for Rheumatology (SIR), Milano, Italy, ⁶Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁷Servicio de Reumatologia, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁸Rheumatology Unit, Spedali Civili of Brescia, Brescia, Italy, ⁹Rheumatology, University Hospital Ramón y Cajal, Madrid, Spain, ¹⁰Department of Rheumatology, University Hospital Ramón y Cajal, Madrid, Spain, ¹¹Rheumatology Unit, University of Pisa, Italy, Pisa, Italy, ¹²Division of Rheumatology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ¹³University of Pavia and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ¹⁴Division of Rheumatology, University of Pavia, IRCCS Foundation Policlinico S. Matteo, Pavia, Italy, ¹⁵UOC Reumatologia, Azienda Ospedaliera Universitaria S. Anna, Ferrara, Italy, ¹⁶Interdisciplinary Department of Medicine (DIM), Rheumatology Unit, University of Bari, Bari, Italy, ¹⁷DIM, Rheumatology Unit, Bari, Italy, ¹⁸Department of Rheumatology, Città della Salute e della Scienza, Torino, Italy, ¹⁹Department of Rheumatology, Città Della Salute e della Scienza, Torino, Italy, ²⁰Rheumatology Unit, Santa Chiara Hospital, Trento, Italy, ²¹Rheumatology, Ospedale di Trento, Trento, Italy, ²²Division of Rheumatology, Mauriziano Hospital, Turin, Italy, ²³New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, Tulane University Lung Center, New Orleans, LA, ²⁴Hospital San Cecilio. Granada, Granada, Spain, ²⁵S. Maria della Misericordia, University of Udine, Italy, Udine, Italy, ²⁶Department for Rheumatology and Clinical Immunology, St. Josef Krankenhaus, University Clinic, Essen, Germany, ²⁷Department of Internal Medicine, Rheumatology and Clinical Immunology, University Hospital Johannes-Gutenberg, Mainz, Germany, ²⁸ACURA Rheumatology Center, Bad Kreuznach, Germany, ²⁹Internal Medicine- Unit of Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center, Rozzano, Italy, ³⁰Rheumatology Department, Polytechnic University of Marche, C. Urbani Hospital, Jesi,, Ancona, Italy, ³¹Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, Genoa, Italy, ³²Osp. San Camillo, Roma, Italy, ³³Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy, ³⁴Rheumatology Unit, Department of Internal Medicine, S.Maria Hospital –IRCCS, Reggio Emilia, Italy, ³⁵Internal Medicine, Rheumatology Unit, Ospedale Guglielmo da Saliceto, Piacenza, Italy, ³⁶Department of Medicine-DIMED, University of Padova, Padova, Italy, ³⁷Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ³⁸Reumatologia, Hospital Universitario Marqués de Valdecilla, IDIVAL, University of Cantabria, Santander, Spain, ³⁹Division of Rheumatology, University and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy
Background/Purpose: arthritis, myositis and interstitial lung disease (ILD) constitute the classic clinical triad of antisynthetase syndrome (ASSD). Even if reported in up to 90% of…
Abstract Number: 1699 • 2014 ACR/ARHP Annual Meeting
Endothelial and Platelet Microparticles As Potential Novel Biomarkers of Peripheral Microvascular Dysfunction in Systemic Sclerosis and Primary Raynaud’s Phenomenon
John D. Pauling^1,2, Daniel Moreno-Martinez³, Fiona Wilkinson⁴, Ben Parker^5,6, Jacqueline A. Shipley¹, Darren Hart¹, Neil J McHugh^1,2 and Yvonne Alexander³, ¹Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, ³Healthcare Science Research Institute, Manchester Metropolitan University, Manchester, United Kingdom, ⁴School of Healthcare Science, Manchester Metropolitan University, Manchester, United Kingdom, ⁵Institute of Inflammation and Repair School of Translation Medicine The University of Manchester, Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, ⁶Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom
Background/Purpose Microparticles (MPs) are membrane-bound vesicles derived from vascular and intravascular cells such as endothelial cells (EMPs) and platelets (PMPs). MPs form during cell activation…
Abstract Number: 1701 • 2014 ACR/ARHP Annual Meeting
Short-Term Effects of Iloprost on Micro-Vessels Hemodynamics in Systemic Sclerosis Patients Evaluated By Laser Doppler Flowmetry
Florenzo Iannone, Cinzia Rotondo, Mariangela Nivuori, Emanuela Praino, Laura Coladonato, Michele Covelli and Giovanni Lapadula, DIM, Rheumatology Unit, Bari, Italy
Background/Purpose Iloprost is a milestone in the treatment of Raynaud’s Phenomenon (RP). However, it has transient hemodynamic effects due to a very short half-time, thereby…
Abstract Number: 1702 • 2014 ACR/ARHP Annual Meeting
Antiphospholipid Antibodies in Systemic Sclerosis: Prevalence and Clinical Significance?
Anjali Shetty¹, Suncica Volkov¹, Claudia Vergara² and William Swedler³, ¹Medicine/Rheumatology, University of Illinois at Chicago, Chicago, IL, ²Rheumatology, University of Illinois Chicago, Chicago, IL, ³Section of Rheumatology, University of Illinois at Chicago, Chicago, IL
Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune disease characterized by collagen deposition and vascular changes of the skin and internal organs, leading ultimately to fibrosis. …
Abstract Number: 1680 • 2014 ACR/ARHP Annual Meeting
an Indirect Comparisons Analysis of Medications Used for Treatment of Raynaud’s Phenomenon
Sampath Manickam¹, Elie Donath², Sandeep Dayanand³ and Jonathan Greer⁴, ¹University of Miami Palm Beach Internal Medicine, West Palm Beach, FL, ²Internal Medicine, University of Miami Miller School of Medicine Palm Beach Regional Campus, Atlantis, FL, ³University of Miami Palm Beach Internal medicine, West palm beach, FL, ⁴Arthritis & Rheumatology Associates, Boynton Beach, FL
An Indirect Comparisons Analysis of Medications used for treatment of Raynaud’s phenomenonBackground/Purpose: There are several pharmacological treatments used for treatment of Raynaud’s phenomenon: calcium channel…
Abstract Number: 737 • 2014 ACR/ARHP Annual Meeting
Reliability of Nailfold Capillary Density Measurement As a Possible Outcome Measure for Systemic Sclerosis-Related Microangiopathy
Graham Dinsdale¹, Tonia Moore², Joanne Manning², Andrea Murray¹, Michael Berks³, Philip Tresadern³, Chris Taylor³, Neil O'Leary⁴, Chris Roberts⁴, John Allen⁵, Marina Anderson⁶, Maurizio Cutolo⁷, Roger Hesselstrand⁸, Kevin Howell⁹, Paula Pyrkotsch⁶, Francesca Ravera⁷, Vanessa Smith¹⁰, Alberto Sulli⁷, Marie Wildt⁸ and Ariane Herrick¹, ¹Centre for Musculoskeletal Research, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²Salford Royal Hospital NHS Foundation Trust, Salford, United Kingdom, ³Centre for Imaging Sciences, University of Manchester, Institute of Population Health, Manchester, United Kingdom, ⁴Centre for Biostatistics, Institute of Population Health, University of Manchester, Manchester, United Kingdom, ⁵Regional Medical Physics Department, Freeman Hospital, Newcastle upon Tyne, United Kingdom, ⁶Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom, ⁷Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ⁸Rheumatology, Lund University, Lund, Sweden, ⁹Institute of Immunity and Transplantation, University College London, Royal Free Campus, London, United Kingdom, ¹⁰Department of Rheumatology, Ghent University Hospital, Ghent, Belgium
Background/Purpose Nailfold videocapillaroscopy allows non-invasive assessment of the microcirculation. Image annotation software allows tracking of changes over time; a potential outcome measure for systemic sclerosis…
Abstract Number: 523 • 2014 ACR/ARHP Annual Meeting
Serum CXCL4 Is Increased in Patients with Primary Sjögren’s Syndrome and Is Associated with Features of Microvascular Impairment
Rosaria Irace¹, Antonella Riccardi¹, Daniela Iacono¹, Luciana Pellecchia¹, Lucia Vicedomini¹, Gabriele Valentini² and Serena Vettori¹, ¹Internal and Experimental Medicine, Second University of Naples, Naples, Italy, ²Internal and Experimental Medicine, Second University of Naples, Napoli, Italy
Background/Purpose CXCL4 is a pleiotropic antiangiogenic and immunomodulatory chemokine. We aimed to investigate CXCL4 serum levels in primary Sjögren’s syndrome (pSS) and looked for associations…
Abstract Number: 3004 • 2014 ACR/ARHP Annual Meeting
Autoantibody-Mediated Raynaud’s Phenomenon: Animal Model and Human Disease
Dana P. Ascherman^1,2, Yunjuan Zang³, Laisel Martinez⁴, Judith Pignac-Kobinger⁵, Irina Fernandez³ and Eric L. Greidinger^3,4, ¹Medicine/Rheumatology, University of Miami, Miami, FL, ²Rheumatology, Miami VAMC, Miami, FL, ³Rheumatology, University of Miami, Miami, FL, ⁴Miami VAMC, Miami, FL, ⁵University of Miami, Miami, FL
Background/Purpose: Raynaud’s Phenomenon (RP) is frequently seen in autoimmune conditions, but an autoimmune basis for RP has not been established. Methods: Sera derived from anti-RNP+…
Abstract Number: 1930 • 2014 ACR/ARHP Annual Meeting
The Value of Repeated Nailfold Capillaroscopy in Raynaud’s Phenomenon in Daily Practice: A Follow-up Study in the Netherlands
B. de Boer¹, J. Meijs¹, J. van Aken², T.W.J. Huizinga¹, A.a. Schouffoer³ and J.K. de Vries-Bouwstra⁴, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Spaarne Ziekenhuis, Hoofddorp, Netherlands, ³Rheumatology, Haga Hospital, The Hague, Netherlands, ⁴Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose Nailfold capillaroscopy is an important tool to differentiate primary Raynaud's phenomenon (PRP) from secondary Raynaud's phenomenon (SRP). Based on possible transition from PRP to…
Abstract Number: 1927 • 2014 ACR/ARHP Annual Meeting
A Retrospective Look at the Recurrence of Digital Ulcers in Patients with Scleroderma after Discontinuation of Oral Treprostinil
Ami A. Shah¹, Elena Schiopu², Soumya Chatterjee³, Mary Ellen Csuka⁴, Tracy Frech⁵, Avram Goldberg⁶, Robert F. Spiera⁷, Stanford L. Peng⁸ and Virginia D. Steen⁹, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology, University of Michigan, Ann Arbor, MI, ³Rheumatic and Immunologic Ds, Cleveland Clinic, Cleveland, OH, ⁴Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ⁵Div of Rheumatology, University of Utah, Salt Lake City, UT, ⁶Div of Rheumatology, North Shore-LIJ Health System, Great Neck, NY, ⁷Rheumatology, Hospital for Special Surgery, New York, NY, ⁸Benaroya Research Institute/Virginia Mason, Seattle, WA, ⁹Department of Rheumatology, Georgetown University Medical Center, Washington, DC
Background/Purpose Ischemic digital ulcers (DU) occur in over 40% of systemic sclerosis (SSc) patients. Treprostinil diolamine, a newer prostacyclin analog that has been developed for…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].